Sars-cov-2 vaccine immunogenicity in patients with gastrointestinal cancer receiving systemic anti-cancer therapy

HIGHLIGHTS

  • who: The Oncologist and collaborators from the Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK Centre for Diagnostics and Antimicrobial Resistance, Clinical Academic Group in Institute for Infection and Immunity, George`s University of have published the Article: SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy, in the Journal: (JOURNAL)
  • how: The authors conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination. To address these concerns the . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?